Takeda Pharmaceutical Company Ltd

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

Special Drug Use Surveillance of Vonoprazan for "Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Low-dose Aspirin: Long-term Use"

Completed

Conditions: Gastric or Duodenal Ulcers

Interventions: Drug: Vonoprazan

First Posted Date: 2017-07-11

Last Posted Date: 2020-03-11

Lead Sponsor: Takeda

Target Recruit Count: 1119

Registration Number: NCT03214094

Locations: 🇯🇵
Takeda Selected Site, Tokyo, Japan

Special Drug Use Surveillance of Leuplin PRO for Injection Kit 22.5 mg for "Prostate Cancer"

Completed

Conditions: Prostate Cancer

Interventions: Drug: Leuprorelin acetate

First Posted Date: 2017-07-06

Last Posted Date: 2019-04-11

Lead Sponsor: Takeda

Target Recruit Count: 333

Registration Number: NCT03209492

Locations: 🇯🇵
Takeda Selected Site, Tokyo, Japan

Special Drug Use Surveillance of Leuprorelin for Injection Kit 22.5 mg in "Premenopausal Breast Cancer"

Completed

Conditions: Premenopausal Breast Cancer

Interventions: Drug: Leuprorelin acetate

First Posted Date: 2017-07-06

Last Posted Date: 2019-11-01

Lead Sponsor: Takeda

Target Recruit Count: 312

Registration Number: NCT03209518

Locations: 🇯🇵
Takeda selected site, Tokyo, Japan

Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)

Phase 2

Active, not recruiting

Conditions: Crohn's Disease
Ulcerative Colitis

Interventions: Drug: Vedolizumab

First Posted Date: 2017-06-22

Last Posted Date: 2024-10-01

Lead Sponsor: Takeda

Target Recruit Count: 59

Registration Number: NCT03196427

Locations: 🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States
🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Children's Center for Digestive Healthcare, Atlanta, Georgia, United States

and more 20 locations

Clinical and Sociodemographic Characterization of Multiple Myeloma Participants With Symptomatic Relapse and/or Refractory Disease in Spain (CharisMMa Study)

Completed

Conditions: Multiple Myeloma

Interventions: Other: No Intervention

First Posted Date: 2017-06-15

Last Posted Date: 2020-10-12

Lead Sponsor: Takeda

Target Recruit Count: 282

Registration Number: NCT03188536

Locations: 🇪🇸
H Marques de Valdecilla, Santander, Cantabria, Spain
🇪🇸
H Universitario de Cabuenes, Gijon, Asturias, Spain
🇪🇸
H Universitario Puerta del Mar, Cadiz, Andalucia, Spain

and more 27 locations

A Study to Evaluate the Effect of the Potent Cytochrome P-450 3A4 (CYP3A4) Inhibitor Itraconazole on the Pharmacokinetics (PK) of TAK-954 in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: TAK-954
Drug: Itraconazole

First Posted Date: 2017-06-01

Last Posted Date: 2019-01-15

Lead Sponsor: Takeda

Target Recruit Count: 10

Registration Number: NCT03173170

Locations: 🇺🇸
Pharmaceutical Research Associates, Inc., Lenexa, Kansas, United States

A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)

Phase 4

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Ixazomib
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2017-06-01

Last Posted Date: 2024-02-12

Lead Sponsor: Takeda

Target Recruit Count: 141

Registration Number: NCT03173092

Locations: 🇺🇸
Saint Agnes Hospital, Baltimore, Maryland, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Pacific Cancer Medical Center, Anaheim, California, United States

and more 30 locations

ADYNOVATE Drug Use-Results Survey

Completed

Conditions: Hemophilia A

Interventions: Biological: ADYNOVATE

First Posted Date: 2017-05-30

Last Posted Date: 2023-12-19

Lead Sponsor: Takeda

Target Recruit Count: 135

Registration Number: NCT03169972

Locations: 🇯🇵
Matsuyama City, Japan, Matsuyama City, Ehime Prefecture, Japan
🇯🇵
Sapporo City, Sapporo City, Hokkaido, Japan
🇯🇵
Kyoto City, Kyoto City, Kyoto Prefecture, Japan

and more 46 locations

NINLARO Capsules Drug Use-Results Survey (All-Case Surveillance) "Relapsed/Refractory Multiple Myeloma"

Completed

Conditions: Relapsed/Refractory Multiple Myeloma

Interventions: Drug: Ixazomib

First Posted Date: 2017-05-30

Last Posted Date: 2023-12-07

Lead Sponsor: Takeda

Target Recruit Count: 774

Registration Number: NCT03169361

Locations: 🇯🇵
Takeda Selected Site, Tokyo, Japan

Study of TAK-935 as an Adjunctive Therapy in Participants With Developmental and/or Epileptic Encephalopathies

Phase 1

Completed

Conditions: Developmental and/or Epileptic Encephalopathies

Interventions: Drug: TAK-935
Drug: Placebo

First Posted Date: 2017-05-25

Last Posted Date: 2021-01-07

Lead Sponsor: Takeda

Target Recruit Count: 18

Registration Number: NCT03166215

Locations: 🇺🇸
Xenoscience, Phoenix, Arizona, United States
🇺🇸
Medsol Clinical Research Center, Port Charlotte, Florida, United States
🇺🇸
University of South Florida, Tampa, Florida, United States

and more 8 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy